Short description
INmune Bio is developing therapies that harness the patient’s immune system to treat cancer.
Description
INmune Bio is a clinical-stage immuno-oncology company focused on harnessing the patient’s immune system to treat cancer.
INKmune, the company’s lead product, primes patient’s NK cells (natural killer cells) to kill cancer. INmune is targeting residual disease, the cancer cells that survive initial treatments that return to cause the cancer relapse. By controlling residual disease, patients may live longer. Using a novel mechanism of action and a precision medicine approach, INKmune therapy should enhance NK cells’ ability to eliminate residual disease.
Last funding
Noaccess
Sign in for full access
Total funding
$$121212
Sign in for full access
Location
La Jolla, California, United States, North America
Founded on
January 1, 2015
Exited on
January 15, 2019
Went public on
January 15, 2019
Stock symbol
INMB
Non-profit?
No
Acquired?
No
Employees count
11-50
Revenue range
$1230 - 4560
Sign in for full access
Investors
Noway Youcantaccess, Noway Youcantaccess, No Way
Sign in for full access
Founders
David J. Moss, Mark Lowdell, Raymond J. Tesi